Endoscopic Procedure Shows Promise in Preventing Weight Regain After GLP-1 Medication Use
Similar Articles
Study Finds Weight Loss via GLP-1 Medications Attracts More Stigma Than Diet and Exercise
Preclinical Study Shows Hybrid Molecule Strategy May Improve Obesity and Diabetes Treatment
Semaglutide Shows Significant Weight Loss Benefits for Older Adults with Obesity
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
New Enzyme Discovery Could Improve GLP-1 Drugs Like Ozempic and Wegovy
An investigational endoscopic procedure called duodenal mucosal resurfacing may help patients maintain weight loss after stopping medications like tirzepatide. Early data from a clinical trial shows participants who received the treatment regained significantly less weight than a control group six months after discontinuing the drug. The full study is ongoing, with more definitive results expected later this year.
Facts First
- Duodenal mucosal resurfacing is an investigational endoscopic treatment that uses heat to renew the lining of the duodenum.
- Early trial data shows the procedure may help prevent weight regain after stopping GLP-1 medications like tirzepatide.
- In a 45-person cohort, the control group regained roughly twice as much weight as the treatment group six months post-procedure.
- No serious complications were reported from the procedure, and most patients resume normal activities within about a day.
- The full REMAIN-1 trial is fully enrolled with over 300 participants, with key six-month data expected in late 2026.
What Happened
Research regarding duodenal mucosal resurfacing (DMR) is being presented at Digestive Disease Week® (DDW) 2026. The REMAIN-1 trial is testing whether renewing the intestinal lining can trigger a metabolic reset to help maintain weight loss after stopping medications like semaglutide or tirzepatide. Current findings are based on an early group of 45 participants with six months of follow-up data. All 45 participants had previously lost at least 15% of their body weight using tirzepatide before discontinuing the drug, losing approximately 40 pounds on average while on therapy. In this cohort, 29 participants received the resurfacing treatment and 16 underwent a sham procedure. Six months after discontinuing medication, participants in the sham control group regained approximately 40% more weight than those who received the actual resurfacing treatment. The control group regained roughly twice as much weight as the group receiving the resurfacing treatment. Patients who underwent more extensive resurfacing regained approximately 7 pounds and maintained more than 80% of their weight loss. The weight regain gap between the treatment and control groups widened between one and six months post-procedure.
Why this Matters to You
If you or someone you know has used a glucagon-like peptide-1 (GLP-1) medication for weight loss, you may be aware that approximately 70% of people who stop these medications eventually regain much of their lost weight. This new procedure could offer a potential path to help maintain that hard-earned weight loss after medication ends. The treatment appears to be low-risk, with no serious complications reported and most patients returning to normal activities within about a day. It may provide a more durable solution for managing obesity.
What's Next
The REMAIN-1 study is fully enrolled and randomized with more than 300 participants. Researchers expect topline six-month data from the pivotal cohort in the early fourth quarter of 2026. A marketing submission for the device is planned for later in 2026. Dr. Shelby Sullivan, the lead author, will present the early cohort results at DDW 2026.